Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:ACIU NASDAQ:ALLO NASDAQ:CADL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$2.84-1.0%$3.04$0.40▼$5.48$67.57M0.2789,378 shs45,151 shsACIUAC Immune$2.54+2.4%$2.19$1.43▼$3.98$249.02M1.61130,250 shs118,723 shsALLOAllogene Therapeutics$1.18+2.6%$1.19$0.86▼$3.78$255.16M0.362.85 million shs2.68 million shsCADLCandel Therapeutics$4.85$5.98$3.79▼$14.60$266.24M-0.9700,010 shs398,783 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+0.70%+5.51%-13.03%+43.50%+313.49%ACIUAC Immune+2.06%+12.73%+16.43%+29.17%-22.01%ALLOAllogene Therapeutics+1.77%+0.88%+4.55%-11.54%-61.15%CADLCandel Therapeutics+1.25%-4.90%-20.36%-1.82%-30.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$2.84-1.0%$3.04$0.40▼$5.48$67.57M0.2789,378 shs45,151 shsACIUAC Immune$2.54+2.4%$2.19$1.43▼$3.98$249.02M1.61130,250 shs118,723 shsALLOAllogene Therapeutics$1.18+2.6%$1.19$0.86▼$3.78$255.16M0.362.85 million shs2.68 million shsCADLCandel Therapeutics$4.85$5.98$3.79▼$14.60$266.24M-0.9700,010 shs398,783 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+0.70%+5.51%-13.03%+43.50%+313.49%ACIUAC Immune+2.06%+12.73%+16.43%+29.17%-22.01%ALLOAllogene Therapeutics+1.77%+0.88%+4.55%-11.54%-61.15%CADLCandel Therapeutics+1.25%-4.90%-20.36%-1.82%-30.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 0.00N/AN/AN/AACIUAC Immune 2.67Moderate Buy$10.00293.70% UpsideALLOAllogene Therapeutics 2.75Moderate Buy$8.44615.63% UpsideCADLCandel Therapeutics 3.00Buy$20.00312.37% UpsideCurrent Analyst Ratings BreakdownLatest ABVC, CADL, ALLO, and ACIU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ACIUAC ImmuneZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/8/2025ACIUAC ImmuneBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/3/2025CADLCandel TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.00 ➝ $7.008/4/2025ALLOAllogene TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform8/4/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral7/9/2025CADLCandel TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$23.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K131.09N/AN/A$0.06 per share47.33ACIUAC Immune$31.02M8.22N/AN/A$1.29 per share1.97ALLOAllogene Therapeutics$20K13,090.92N/AN/A$2.01 per share0.59CADLCandel Therapeutics$120K2,218.88N/AN/A$1.41 per share3.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$4.90M-$0.170.00∞N/A-963.46%-46.76%-23.02%11/12/2025 (Estimated)ACIUAC Immune-$57.83M-$0.580.00N/AN/A-174.94%-49.35%-23.16%11/4/2025 (Estimated)ALLOAllogene Therapeutics-$257.59M-$1.110.00N/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)CADLCandel Therapeutics-$55.18M-$0.690.00N/AN/AN/A-41.00%-26.81%11/13/2025 (Estimated)Latest ABVC, CADL, ALLO, and ACIU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CADLCandel Therapeutics-$0.17-$0.09+$0.08-$0.09N/AN/A8/13/2025Q2 2025ABVCABVC BioPharmaN/A-$0.13N/A-$0.13N/AN/A8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/A8/5/2025Q2 2025ACIUAC Immune-$0.20-$0.25-$0.05-$0.25$1.98 million$1.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/AACIUAC ImmuneN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.420.42ACIUAC ImmuneN/A1.331.33ALLOAllogene TherapeuticsN/A8.928.92CADLCandel Therapeutics0.017.047.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%ACIUAC Immune51.36%ALLOAllogene Therapeutics83.63%CADLCandel Therapeutics13.93%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma17.10%ACIUAC Immune4.60%ALLOAllogene Therapeutics13.20%CADLCandel Therapeutics16.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3023.54 million19.52 millionNot OptionableACIUAC Immune140100.41 million95.79 millionOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableCADLCandel Therapeutics6054.90 million45.78 millionOptionableABVC, CADL, ALLO, and ACIU HeadlinesRecent News About These CompaniesCandel Therapeutics, Inc. $CADL Shares Bought by Acorn Capital Advisors LLCSeptember 11, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Downgraded by Wall Street Zen to SellSeptember 8, 2025 | marketbeat.comCandel Therapeutics: Potentially The Next Exciting Oncology StorySeptember 7, 2025 | seekingalpha.comNuveen LLC Buys Shares of 78,145 Candel Therapeutics, Inc. $CADLSeptember 7, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Lowered to "Neutral" Rating by Bank of AmericaSeptember 6, 2025 | americanbankingnews.comCandel Therapeutics (NASDAQ:CADL) Downgraded to Sell Rating by Wall Street ZenSeptember 6, 2025 | americanbankingnews.comCandel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough TumorsSeptember 5, 2025 | seekingalpha.comCandel Therapeutics (NASDAQ:CADL) Rating Lowered to "Neutral" at Bank of AmericaSeptember 5, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 544,794 Shares of Candel Therapeutics, Inc. $CADLSeptember 4, 2025 | marketbeat.comB of A Securities Downgrades Candel Therapeutics (CADL)September 4, 2025 | msn.comErasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalystsSeptember 3, 2025 | msn.comCandel Therapeutics downgraded to Neutral at BofA on lack of catalystsSeptember 3, 2025 | msn.comCandel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory BoardSeptember 2, 2025 | ca.finance.yahoo.comCandel Therapeutics adds immunotherapy expert to Research Advisory BoardSeptember 2, 2025 | proactiveinvestors.comCandel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.September 2, 2025 | globenewswire.comCandel Therapeutics, Inc. (NASDAQ:CADL) Receives Consensus Rating of "Buy" from BrokeragesSeptember 1, 2025 | marketbeat.comCandel Therapeutics, Inc. Announces Participation in Upcoming Investor ConferencesAugust 28, 2025 | quiverquant.comQCandel Therapeutics to Participate in Upcoming Investor Conferences in SeptemberAugust 28, 2025 | globenewswire.comCandel Therapeutics Extends Lease Agreement in NeedhamAugust 22, 2025 | msn.comCandel Therapeutics Advances with Promising Cancer TherapiesAugust 18, 2025 | tipranks.comCandel Therapeutics (NASDAQ:CADL) Posts Earnings Results, Beats Expectations By $0.08 EPSAugust 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 2025Kratos Keeps Climbing After Q2, But Valuation Risk LoomsBy Leo Miller | August 18, 2025ABVC, CADL, ALLO, and ACIU Company DescriptionsABVC BioPharma NASDAQ:ABVC$2.84 -0.03 (-1.05%) Closing price 04:00 PM EasternExtended Trading$2.85 +0.01 (+0.32%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.AC Immune NASDAQ:ACIU$2.54 +0.06 (+2.42%) Closing price 04:00 PM EasternExtended Trading$2.50 -0.04 (-1.57%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Allogene Therapeutics NASDAQ:ALLO$1.18 +0.03 (+2.61%) Closing price 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.42%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Candel Therapeutics NASDAQ:CADL$4.85 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$4.90 +0.05 (+1.11%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
